
11 Jan 2019 Research
Myelofibrosis: Finding new ways to treat patients
Myelofibrosis is a fatal bone marrow cancer. The disease is caused by excessive secretion of factors by cancerous platelet-producing cells called megakaryocytes. These secretions cause the replacement of normal bone marrow tissue with fibrous scar tissue.
Dr Chen’s team can successfully recreate this pathological bone marrow environment in the laboratory, and their preliminary research data shows that reduced levels of a protein complex called FANCcore leads to more myelofibrosis.
Dr Chen’s team hypothesise that loss of the protein complex FANCcore increases the growth of myelfibrosis by altering megakaryocytes. Dr Chen uses both human tissue cultures and mouse models to examine the cellular and molecular changes to megakaryocytes following the absence of the FANCcore complex and to understand how these changes cause myelofibrosis.
The team hopes that by focusing on the role of FANCcore in megakaryocyte biology, they can reveal new ways to treat myelofibrosis.
Related posts
27 August 2020
Leukaemia UK appoints new CEO
The trustees of Leukaemia UK are delighted to announce that they have appointed Fiona Hazell as CEO of Leukaemia UK. Fiona brings a strong track record in not-for-profit leadership, starting her role on 9th September 2020.
18 May 2022
World Blood Cancer Day interview with Dr Pramila Krishnamurthy
On 28th May the global blood cancer community comes together to mark World Blood Cancer Day, this campaign calls for support of those with blood cancer and encourages people to become stem cell donors.
12 December 2022
Widespread coverage of new leukaemia therapy shows promise in first trial patient
As you may have seen in the news over the weekend, a clinical trial investigating a new leukaemia treatment has shown promising results. As part of the trial, funded by…
19 August 2022
Leukaemia Care and Leukaemia UK announce financial support collaboration
Leukaemia Care and Leukaemia UK are pleased to announce a collaboration to provide financial support to people affected by leukaemia, through the financial hardship fund. Leukaemia Care have provided 364…